SUBSCRIBE
Login
Back to all insights

Max Mobility / Permobil Expands Worldwide Recall of SmartDrive SpeedControl Dial — Investigative report and manufacturer action plan

Looking For Service?

Published: August 12, 2025
Source: Company announcement posted on FDA recalls page. U.S. Food and Drug Administration

Executive summary (quick take)

Max Mobility / Permobil has announced a voluntary, worldwide expanded recall and market removal of all SpeedControl Dials used with the SmartDrive MX2+ power-assist device. The action covers every SpeedControl Dial manufactured and distributed between April 25, 2022 and July 8, 2025 after a design issue was linked to intermittent electrical connection problems that can cause continued drive or involuntary movement of the motor — events that have caused injuries including fractures and a concussion. The company has suspended distribution and instructs users to stop using the dial and switch to alternate controls immediately. U.S. Food and Drug Administration

What happened (facts & timeline)

  • Announcement date: August 12, 2025 (company announcement, posted by FDA). U.S. Food and Drug Administration
  • Scope: Expanded recall supersedes earlier Class I recalls first initiated December 20, 2024 (and expanded March 28, 2025). The current action now covers all SpeedControl Dials in the market, including replacements issued under prior recalls. U.S. Food and Drug Administration
  • Manufacturing / distribution window: All SpeedControl Dials manufactured and distributed April 25, 2022 → July 8, 2025. U.S. Food and Drug Administration

The technical problem (what’s failing)

Investigations identified a design issue in the SpeedControl Dial leading to an intermittent electrical connection between the dial and the SmartDrive MX2+ motor. That intermittent connection can cause either:

  • Continued drive: the motor fails to stop when the dial is pressed inward, or
  • Involuntary movement: motor activates without intentional user input while the dial is at zero (standby) and the dial light is flashing.

These failure modes can occur at low or high speeds; at higher speeds, the potential for serious injury (bone fracture, concussion) rises substantially. U.S. Food and Drug Administration

Reported complaints & injuries (load-bearing numbers)

  • Total complaints cited historically: Max Mobility/Permobil received 781 complaints associated with a prior PCBA design issue. From ongoing monitoring they identified 54 complaints that may be related to the current design problem. U.S. Food and Drug Administration
  • Serious injuries reported: Of the earlier complaint set, five (5) were classified as serious (fractures or a concussion); the current set includes two (2) complaints with serious injuries. U.S. Food and Drug Administration

Which parts are affected

All SpeedControl Dials — part numbers listed explicitly by the company include:

Immediate guidance for users, caregivers and facilities

If you use a SpeedControl Dial:

  1. Stop using the SpeedControl Dial immediately to reduce the risk of continued or involuntary drive. U.S. Food and Drug Administration
  2. Switch to an alternate control method right away. Options include:
    • Wired SwitchControl (mono-jack compatible) with an optional Buddy Button for large tactile feedback; or
    • Wireless control via SmartDrive MX2+ App using compatible wearables (Apple Watch, Samsung Galaxy Watch). U.S. Food and Drug Administration
  3. Contact your SmartDrive provider or Permobil technical support for assistance and replacement guidance. Hotline numbers and email were provided in the company announcement. U.S. Food and Drug Administration

If you are a distributor or retailer:

  • Remove all SpeedControl Dials from sellable/distribution inventory immediately and follow the company’s return/removal instructions. U.S. Food and Drug Administration

Risk to health and safety — practical scenarios

  • Low-speed event: may cause minor cuts, bruises, or soreness.
  • High-speed or complex-environment event: unexpected continued or involuntary movement can lead to falls, collisions, or tip-over risks, with potential for bone fractures or head injuries — reported outcomes in the complaint set. People near the user (pedestrians, caregivers) may also be at risk of being struck. U.S. Food and Drug Administration

What Permobil / Max Mobility has already done

  • Suspended distribution of the SpeedControl Dial; the dial is no longer available as a control option for the SmartDrive MX2+.
  • Committed to replacing SpeedControl Dials with alternate controls and to provide instructions via their support hub.
  • Issued notifications to customers starting August 12, 2025, and provided technical support and contact information for order inquiries and assistance. U.S. Food and Drug Administration

Regulatory context & likely next steps

  • FDA posted the company announcement as a public service; the agency has been notified of the voluntary recall. The recall supersedes earlier Class I actions (Z-1116-2025/Z-1117-2025) and will be tracked through FDA’s recall monitoring processes. U.S. Food and Drug Administration
  • Possible regulatory follow-up includes FDA inspection(s) of design controls, complaint handling, CAPA effectiveness, and production records. Given prior repeated complaints and injuries, expect heightened scrutiny on the vendor’s design validation, supplier controls, and postmarket surveillance.

Investigative analysis — probable root causes (expert view)

The company attributes the failures to a PCBA/design issue that creates an intermittent connection. Root-cause lines to explore include:

  • Mechanical tolerance / connector wear (vibration, ingress, flexing) leading to intermittent contact.
  • PCB footprint or solder joint defects (cold solder, insufficient fillet, microfractures).
  • Poor strain relief or cable routing causing repeated stress at the connection point.
  • Electromagnetic interference or software debouncing logic insufficient to ignore spurious signals from intermittent connections.
  • Supplier variability for the connector or wiring harnesses introduced when the part was redesigned.

A thorough failure-modes-and-effects analysis (FMEA), focused re-test of PCBA assemblies under mechanical/fatigue/thermal cycling, and traceability to component lot numbers are needed. (These are suggested investigative steps; the company’s announcement indicates PCBA problems were already a focus.) U.S. Food and Drug Administration

Action checklist for the manufacturer (what must be done now)

1) Field safety & customer support (immediate — days)

  • Ensure all customers have received direct notice and that clinical partners (ATP/OT vendors, home health providers) are alerted. U.S. Food and Drug Administration
  • Provide clear swap/upgrade paths and logistical support for replacing dials with SwitchControl or app-based control (loaner programs if needed). U.S. Food and Drug Administration
  • Set up a dedicated hotline, scheduling portal, and claims process for injuries and returns; triage serious injury reports for immediate medical follow-up and evidence collection. U.S. Food and Drug Administration

2) Product containment & traceability (immediate → 2 weeks)

  • Quarantine remaining inventory and disable sale or shipment of any SpeedControl Dials. Document serial numbers, lot codes, and distribution chains for rapid recall accounting. U.S. Food and Drug Administration

3) Forensics & engineering fixes (2–8 weeks)

  • Launch detailed PCBA forensic analysis (X-ray, solder/assembly microscopy, cross-sections). Test connectors for insertion/withdrawal cycles, vibration, thermal cycling, humidity exposure, and flex fatigue.
  • If connector/system design is flawed, implement design change (mechanical strain relief, connector change, sealed connector, PCB redesign), and perform updated verification/validation per IEC 60601-1 and applicable medical device standards.
  • Evaluate firmware/software mitigations (signal debouncing, watchdogs, safe-stop failsafes) while hardware fixes are progressed.

4) Quality systems & CAPA (ongoing)

  • Strengthen incoming inspection for connector components, revise supplier specifications, and tighten acceptance criteria.
  • Update Design History File (DHF) with new risk assessments and test evidence; execute corrective and preventive actions (CAPA) and verify their effectiveness.
  • Re-run accelerated life testing and human factors validation with representative users.

5) Regulatory & compliance (immediate → ongoing)

  • Maintain transparent communications with FDA (and other notified bodies / competent authorities globally). Provide periodic status updates including root-cause, corrective actions, and field remediation plans. U.S. Food and Drug Administration
  • Prepare labeling / IFU updates if alternative controls or warnings are required.
  • Be inspection-ready: assemble documentation for complaint investigations, CAPA records, validation results, and distribution logs.

6) Safety surveillance and legal (ongoing)

  • Intensify postmarket surveillance to detect any residual failure patterns after replacements are in the field.
  • Engage legal counsel to review liability exposure and to manage reports of serious injury; ensure medical follow-up and possible compensation pathways are defined.

Communications: templates & transparency

  • Release a clear FAQ for end users explaining risk, steps to stop use, and how to obtain replacements.
  • Send Dear HCP/Distributor letters with triage instructions and return logistics.
  • Publish a step-by-step video showing how to switch to alternate controls (app pairing, SwitchControl/Buddy Button setup). Permobil has already posted hub links for additional instructions. U.S. Food and Drug Administration

Practical guidance for clinicians, therapists and ATP/OT providers

  • Immediately check clients who use SpeedControl Dials and confirm the dial is removed. Schedule same-day follow-ups for clients who may lack alternative control methods. U.S. Food and Drug Administration
  • Document counseling and functional impact; report any suspected device-related adverse events to FDA MedWatch and to Permobil’s technical support. U.S. Food and Drug Administration

Closing assessment — why this matters

This expanded recall reflects an issue that is both widespread across production (all dials in market) and safety-critical: an intermittent electrical connection can unpredictably change device behavior, creating real risk of injury to users and bystanders. The recall’s breadth (covering every SpeedControl Dial back to the product introduction in 2022) suggests a fundamental design or design-control gap rather than an isolated manufacturing batch problem — so the manufacturer’s response must be systemic, transparent, and fast. U.S. Food and Drug Administration

Where to get help / report problems

Contact us: company@shudarsana.com

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.

error: Content is protected !!